Summary of studies on renal and patient survival in patients with AAV based on ANCA serotype (C-/PR3-ANCA and P-/MPO-ANCA).
Study (reference) | Year | No. Patients | Renal Involvement | Specialty | Comparison | Case Identification | ESRD | Death |
---|---|---|---|---|---|---|---|---|
Geffriaud-Ricouard, et al16 | 1993 | 83 | 92% | Nephrology | PR3 vs MPO | Single center | No difference | No difference |
Franssen, et al18 | 1995 | 92 | 75% | “Mixed” | PR3 vs MPO | Teaching hospitals | No difference | No difference |
Hogan, et al13 | 1996 | 107 | 100% | Nephrology | C vs P-ANCA | Specialized units (Glomerular Disease Collaborative Network) | No difference | Worse for C-ANCA |
Westman, et al19 | 1998 | 123 | 100% | Nephrology | PR3 vs MPO | Single center | Worse for PR3# | No difference |
Franssen, et al10 | 1998 | 92 | 75% | “Mixed” | PR3 vs MPO | Teaching hospitals | NR | No difference |
Vizjak, et al24 | 2003 | 135 | 100% | “Mixed” | PR3 vs MPO | Single center | Worse MPO | No difference |
Weidner, et al12 | 2004 | 80 | 100% | Nephrology | PR3 vs MPO | Single center | No difference | Worse for PR3 |
Rihova, et al25 | 2005 | 61 | 100% | Nephrology | C-vs P-ANCA | Single center | No difference | No difference |
Flossmann, et al26 | 2011 | 535 | 100% | Mixed | PR3 vs MPO | Multicenter clinical trials | NR | Worse for MPO |
Lionaki, et al5 | 2012 | 502 | 97% | Nephrology | PR3 vs MPO | Specialized units (Glomerular Disease Collaborative Network) | Worse for MPO | Worse for MPO |
de Joode, et al20 | 2013 | 212 | 100% | Nephrology | MPO vs PR3 | Single center | Worse for MPO | Worse for MPO* |
Present study | 2013 | 183 | 76% | “Mixed” | PR3 vs MPO | Population-based | Worse for MPO | No difference |